To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Wednesday, November 30, 2022
Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths
Two
deaths have dimmed the initial glow surrounding Eisai and Biogen’s next
Alzheimer’s disease therapy lecanemab. But the Japanese company now has
more answers on the risks patients may need to learn to accept to receive
treatment.
No comments:
Post a Comment